Beryl Drugs Ltd
₹ 23.5
0.00%
16 Jun
- close price
About
Incorporated in 1993, Beryl Drugs Ltd
is in the business of pharmaceuticals manufacturing[1]
Key Points
- Market Cap ₹ 11.9 Cr.
- Current Price ₹ 23.5
- High / Low ₹ 30.0 / 15.9
- Stock P/E 28.4
- Book Value ₹ 19.5
- Dividend Yield 0.00 %
- ROCE 7.18 %
- ROE 4.33 %
- Face Value ₹ 10.0
Pros
- Company has reduced debt.
- Debtor days have improved from 79.1 to 39.5 days.
- Company's working capital requirements have reduced from 55.1 days to 39.3 days
Cons
- Though the company is reporting repeated profits, it is not paying out dividend
- The company has delivered a poor sales growth of 6.60% over past five years.
- Promoter holding is low: 27.5%
- Company has a low return on equity of 6.42% over last 3 years.
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Healthcare Healthcare Pharmaceuticals & Biotechnology Pharmaceuticals
Loading peers table ...
Quarterly Results
Figures in Rs. Crores
Profit & Loss
Figures in Rs. Crores
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 13.23 | 12.99 | 10.90 | 15.08 | 12.81 | 12.78 | 14.03 | 14.48 | 26.84 | 26.73 | 21.15 | 19.31 | |
| 12.50 | 12.49 | 10.96 | 14.04 | 11.78 | 11.87 | 12.58 | 14.04 | 24.84 | 24.45 | 19.91 | 16.89 | |
| Operating Profit | 0.73 | 0.50 | -0.06 | 1.04 | 1.03 | 0.91 | 1.45 | 0.44 | 2.00 | 2.28 | 1.24 | 2.42 |
| OPM % | 5.52% | 3.85% | -0.55% | 6.90% | 8.04% | 7.12% | 10.33% | 3.04% | 7.45% | 8.53% | 5.86% | 12.53% |
| 0.18 | 0.37 | 0.27 | 0.69 | 0.24 | 0.23 | 0.64 | 0.16 | 0.27 | 0.40 | 1.41 | -0.00 | |
| Interest | 0.26 | 0.21 | 0.20 | 0.13 | 0.15 | 0.32 | 0.47 | 0.46 | 0.47 | 0.47 | 0.54 | 0.34 |
| Depreciation | 0.52 | 0.41 | 0.38 | 0.33 | 0.32 | 0.66 | 1.27 | 1.09 | 0.81 | 1.20 | 1.25 | 1.49 |
| Profit before tax | 0.13 | 0.25 | -0.37 | 1.27 | 0.80 | 0.16 | 0.35 | -0.95 | 0.99 | 1.01 | 0.86 | 0.59 |
| Tax % | 38.46% | 32.00% | 18.92% | 22.05% | 26.25% | 68.75% | 31.43% | -30.53% | 22.22% | 23.76% | 33.72% | 27.12% |
| 0.08 | 0.17 | -0.45 | 0.99 | 0.59 | 0.05 | 0.24 | -0.66 | 0.77 | 0.77 | 0.58 | 0.42 | |
| EPS in Rs | 0.16 | 0.34 | -0.89 | 1.95 | 1.16 | 0.10 | 0.47 | -1.30 | 1.52 | 1.52 | 1.14 | 0.83 |
| Dividend Payout % | -0.00% | -0.00% | -0.00% | -0.00% | -0.00% | -0.00% | -0.00% | -0.00% | -0.00% | -0.00% | -0.00% | -0.00% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | 4% |
| 5 Years: | 7% |
| 3 Years: | -10% |
| TTM: | -9% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | 9% |
| 5 Years: | 44% |
| 3 Years: | -18% |
| TTM: | -28% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | -4% |
| 5 Years: | 25% |
| 3 Years: | 13% |
| 1 Year: | 19% |
| Return on Equity | |
|---|---|
| 10 Years: | 3% |
| 5 Years: | 4% |
| 3 Years: | 6% |
| Last Year: | 4% |
Balance Sheet
Figures in Rs. Crores
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 5.09 | 5.09 | 5.09 | 5.09 | 5.09 | 5.09 | 5.09 | 5.09 | 5.09 | 5.09 | 5.09 | 5.09 |
| Reserves | 1.40 | 1.57 | 0.79 | 1.57 | 2.43 | 2.53 | 2.84 | 2.20 | 2.97 | 3.83 | 4.41 | 4.79 |
| 1.72 | 1.69 | 1.72 | 1.48 | 3.25 | 5.23 | 5.12 | 5.29 | 4.54 | 5.09 | 4.07 | 2.44 | |
| 2.71 | 1.80 | 2.85 | 2.69 | 3.80 | 4.07 | 5.60 | 5.25 | 4.92 | 3.48 | 2.39 | 2.64 | |
| Total Liabilities | 10.92 | 10.15 | 10.45 | 10.83 | 14.57 | 16.92 | 18.65 | 17.83 | 17.52 | 17.49 | 15.96 | 14.96 |
| 2.43 | 2.44 | 2.25 | 2.22 | 1.96 | 8.60 | 7.52 | 6.04 | 6.03 | 6.17 | 6.20 | 7.04 | |
| CWIP | 0.24 | -0.00 | -0.00 | 0.08 | 6.24 | -0.00 | -0.00 | -0.00 | -0.00 | -0.00 | -0.00 | -0.00 |
| Investments | 0.68 | 0.68 | 0.49 | 0.22 | 0.48 | 0.56 | 0.12 | 0.16 | 0.15 | -0.00 | -0.00 | -0.00 |
| 7.57 | 7.03 | 7.71 | 8.31 | 5.89 | 7.76 | 11.01 | 11.63 | 11.34 | 11.32 | 9.76 | 7.92 | |
| Total Assets | 10.92 | 10.15 | 10.45 | 10.83 | 14.57 | 16.92 | 18.65 | 17.83 | 17.52 | 17.49 | 15.96 | 14.96 |
Cash Flows
Figures in Rs. Crores
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 0.70 | -0.13 | 0.37 | -0.10 | 3.35 | 0.18 | 0.34 | -0.29 | 2.48 | 0.82 | 2.64 | 3.65 | |
| 0.02 | 0.17 | 0.32 | -0.03 | -5.01 | -1.55 | 0.26 | 0.54 | -1.30 | -1.08 | -0.40 | -2.16 | |
| -0.09 | -0.23 | -0.19 | -0.36 | 1.62 | 1.67 | -0.54 | -0.43 | -1.17 | 0.10 | -1.55 | -2.03 | |
| Net Cash Flow | 0.63 | -0.19 | 0.50 | -0.49 | -0.04 | 0.30 | 0.06 | -0.18 | 0.01 | -0.16 | 0.69 | -0.54 |
| Free Cash Flow | 0.47 | -0.33 | 0.19 | -0.01 | -2.87 | -1.70 | 0.10 | 0.10 | 1.73 | -0.51 | 1.35 | -0.17 |
| CFO/OP | 125% | 6% | -833% | 1% | 350% | 36% | 25% | -43% | 127% | 45% | 227% | 157% |
Ratios
Figures in Rs. Crores
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 102.08 | 100.59 | 102.47 | 116.91 | 98.02 | 98.53 | 118.11 | 112.17 | 93.83 | 103.51 | 94.23 | 39.51 |
| Inventory Days | 64.34 | 65.28 | 151.29 | 53.10 | 39.74 | 486.67 | 1,135.00 | 245.67 | 116.93 | |||
| Days Payable | 69.91 | 34.34 | 65.24 | 57.03 | 93.60 | 755.17 | 1,110.00 | 758.08 | 53.42 | |||
| Cash Conversion Cycle | 96.50 | 131.54 | 188.52 | 112.97 | 44.16 | -169.97 | 143.11 | 112.17 | -418.57 | 103.51 | 94.23 | 103.02 |
| Working Capital Days | 38.35 | 58.44 | 67.31 | 71.89 | -6.55 | 13.99 | 38.76 | 47.14 | 46.51 | 57.90 | 68.00 | 39.32 |
| ROCE % | 5.20% | 5.56% | -2.26% | 11.94% | 9.94% | 4.06% | 2.86% | -3.82% | 11.60% | 11.05% | 10.15% | 7.18% |
Insights
In beta| Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|
| Number of Channel Partners Count |
|
|||||
| Number of Corporate Customers Count |
||||||
| Number of Marketing Offices Count |
||||||
| Trade Receivable Turnover Ratio Times |
||||||
Requires Premium
Requires Premium
Extracted by Screener AI
Documents
Announcements
-
Announcement under Regulation 30 (LODR)-Change in Registered Office Address
4h - Registered office shifted within Indore from Kanchan Bagh to Bicholi, effective 1 July 2026.
-
Board Meeting Outcome for OUTCOME OF BOARD MEETING
4h - Board approved shifting registered office in Indore from 133 Kanchan Bagh to 29 Neer Nagar on 16 June 2026.
- Disclosures under Reg. 29(1) of SEBI (SAST) Regulations, 2011 12 Jun
- Disclosures under Reg. 29(1) of SEBI (SAST) Regulations, 2011 11 Jun
- Disclosures under Reg. 29(1) of SEBI (SAST) Regulations, 2011 10 Jun
Annual reports
-
Financial Year 2025
from bse
-
Financial Year 2024
from bse
-
Financial Year 2023
from bse
-
Financial Year 2022
from bse
-
Financial Year 2021
from bse
-
Financial Year 2020
from bse
-
Financial Year 2019
from bse
-
Financial Year 2018
from bse
-
Financial Year 2017
from bse
-
Financial Year 2016
from bse
-
Financial Year 2015
from bse
-
Financial Year 2014
from bse
-
Financial Year 2013
from bse
-
Financial Year 2012
from bse
-
Financial Year 2011
from bse
Business Overview:[1]
BDL is mainly engaged in the domestic, institutions, and export supply of bulk drugs, pharmaceuticals, and healthcare products
like I.V. Fluids and Small Volume Injectables.
It manufactures and markets a range of branded, generic pharmaceutical formulations through its nationwide sales and distribution network and provides research and development, contract manufacturing services, and veterinary products.